Skye Bioscience Phase 2a trial of SBI-100 OE fails primary endpoint; discontinues ophthalmology program

Skye Bioscience, Inc.

Phase 2a trial of SBI-100 in 56 patients with POAG or OHT did not meet primary IOP endpoint vs placebo.
Drug safe; all patients completed study with no early discontinuations due to adverse events.
Company discontinues all SBI-100 development and ophthalmology pipeline; focuses on obesity program with Nimacimab.
Phase 2 obesity trial of Nimacimab expected to start Q3 2024; cash runway extended into 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.